BOTH CIRCULATING AND CLOT-BOUND PLASMINOGEN-ACTIVATOR INHIBITOR-1 INHIBIT ENDOGENEOUS FIBRINOLYSIS IN THE RAT

被引:36
作者
REILLY, CF
FUJITA, T
MAYER, EJ
SIEGFRIED, ME
机构
[1] Department of Pharmacology, Merck Sharp and Dohme Res. Labs., West Point, PA
[2] Department of Pharmacology, Merck Sharp and Dohme Res. Labs., West Point
来源
ARTERIOSCLEROSIS AND THROMBOSIS | 1991年 / 11卷 / 05期
关键词
PLASMINOGEN ACTIVATOR INHIBITOR-1; FIBRIN; THROMBOSIS; FIBRINOLYSIS; PLASMINOGEN ACTIVATORS; TISSUE-TYPE PLASMINOGEN ACTIVATOR;
D O I
10.1161/01.ATV.11.5.1276
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The effects of both clot-bound and circulating plasminogen activator inhibitor-1 (PAI-1) on endogenous fibrinolysis were investigated in a rat model of pulmonary embolism. Iodine-125 fibrin(ogen)-labeled blood-clot homogenates were delivered through the left jugular vein to the lung microvasculature, and the subsequent extent of the clot lysis was monitored by measuring the release of I-125-fibrin degradation products (FDPs) into the blood. Clots that had incorporated activated PAI-1 ex vivo were subsequently protected from dissolution in vivo in a dose-responsive manner (half-maximal concentration [IC50] = 4.3-mu-g/ml). PAI-1-containing clots also resisted lysis, as measured by the release of the specific FDP D-dimer. Plasma levels of plasminogen activator (PA) and PAI activity were unaltered by administration of PAI-1-containing clots, and the clot-protective effects of clot-bound PAI-1 were reversed by exogenous tissue-type plasminogen activator administration. Clot lysis was also inhibited in a dose-responsive manner (IC50 = 58-mu-g/kg) by intravenous bolus delivery of activated PAI-1 to the circulation. The clot-protective effects of circulating PAI-1 were correlated with dose-dependent increases in plasma PAI-1 antigen and activity levels and decreases in plasma PA levels (IC50 = 37-mu-g/ml). There was no evidence of any accumulation of circulating PAI-1 in the lungs. Latent PAI-1, whether delivered with or delivered after the clot homogenates, did not affect the clot-lytic process. Activated and latent PAI-1 was cleared from the circulation in a monophasic manner, with a half-life of approximately 32 and 7 minutes, respectively. The results indicate that both clot-bound and circulating PAI-1 are potent inhibitors of fibrinolysis in vivo. Clot-bound PAI-1 may inhibit PAs in the immediate vicinity of the clots, whereas circulating PAI-1 may act systemically by controlling overall levels of PAs present in the blood.
引用
收藏
页码:1276 / 1286
页数:11
相关论文
共 38 条
[21]  
KRUITHOF EKO, 1987, BLOOD, V70, P1645
[22]  
LEVI M, 1990, FIBRINOLYSIS, V4, pA174
[24]  
LUCAS MA, 1983, J BIOL CHEM, V258, P4249
[25]  
MAYER EJ, 1990, BLOOD, V76, P1514
[26]   PLASMINOGEN-ACTIVATOR INHIBITOR IN THE BLOOD OF PATIENTS WITH CORONARY-ARTERY DISEASE [J].
PARAMO, JA ;
COLUCCI, M ;
COLLEN, D ;
VANDEWERF, F .
BRITISH MEDICAL JOURNAL, 1985, 291 (6495) :573-574
[27]  
REILLY CF, 1991, J BIOL CHEM, V266, P9419
[28]   PLASMINOGEN-ACTIVATOR INHIBITOR-1 SUPPRESSES ENDOGENOUS FIBRINOLYSIS IN A CANINE MODEL OF PULMONARY-EMBOLISM [J].
REILLY, CF ;
FUJITA, T ;
HUTZELMANN, JE ;
MAYER, EJ ;
SHEBUSKI, RJ .
CIRCULATION, 1991, 84 (01) :287-292
[29]   THE EFFECT OF EXOGENOUS PLASMINOGEN-ACTIVATOR INHIBITOR-1 IN A CANINE MODEL OF OCCLUSIVE THROMBUS FORMATION [J].
REILLY, CF ;
MAYER, EJ ;
SITKO, GR ;
HUTZELMANN, JE ;
GARDELL, SJ ;
SHEBUSKI, RJ .
FIBRINOLYSIS, 1991, 5 (02) :99-104
[30]  
RIJKEN DC, 1982, J BIOL CHEM, V257, P2920